Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma (Q24243100)

11

0 references

Nicole Skoetz

3

0 references

Martin Dreyling

7

0 references

Guido Schwarzer

9

0 references

Sven Trelle

4

0 references

Michael Hallek

10

Michael Hallek

0 references

Marcel Reiser

6

Marcel Reiser

0 references

Thilo Kober

5

Thilo Kober

0 references

Michael Jerosch-Herold

8

Michael Herold

0 references

author name string

Holger Schulz

Cochrane Database of Systematic Reviews

1

0 references

publication date

17 October 2007

0 references

published in

0 references

cites work

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Calculating the number needed to treat for trials where the outcome is time to an event

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Treatment of mantle cell lymphoma: current approach and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Improved survival of follicular lymphoma patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

Stage I-II follicular lymphoma. Treatment results for 76 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021

Pounding in the neck in supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021

Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003805.PUB2

7 January 2021